Format

Send to

Choose Destination
Bioanalysis. 2016;8(5):413-24. doi: 10.4155/bio.15.255. Epub 2016 Feb 19.

A clinical validation study for application of DBS in therapeutic drug monitoring of antidepressants.

Author information

1
Department of Pharmacy, Section Pharmacotherapy & Pharmaceutical Care, University of Groningen, 9712 CP Groningen, The Netherlands.
2
Unit PharmacoEpidemiology & PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen, 9712 CP Groningen, The Netherlands.
3
Department of Clinical Pharmacy & Pharmacology, University Medical Center Groningen, University of Groningen, 9712 CP Groningen, The Netherlands.
4
Laboratory for Drug Analysis & Toxicology, Diaconessen Hospital Meppel & Bethesda Hospital Hoogeveen, Meppel, The Netherlands.

Abstract

BACKGROUND:

A bridging study of plasma and DBS concentrations for therapeutic drug monitoring of antidepressants was performed. RESULTS & METHODOLOGY: Potassium-based hematocrit analysis was included. In addition, we defined acceptance criteria based on the differences between individual data points of plasma and DBS concentrations. These criteria were applied to test acceptability of error found in predicted nortriptyline plasma concentrations. Potassium-based hematocrit predicted a negative bias for DBS concentrations of amitriptyline, but not for the other compounds. To predict plasma concentrations of antidepressants based on DBS concentrations, a factor of 0.8, 0.65, 0.84 and 0.78 was found for nortriptyline, desmethylclomipramine, venlafaxine and desmethylvenlafaxine, respectively.

DISCUSSION & CONCLUSION:

Application of the factor and newly formulated acceptance criteria demonstrated prediction of nortriptyline plasma concentrations based on DBS concentrations.

KEYWORDS:

DBS; antidepressants; clinical validation; plasma; therapeutic drug monitoring

PMID:
26893105
DOI:
10.4155/bio.15.255
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center